Dopamine partial agonists: A new class of antipsychotic

CNS Drugs

Volumn 18, Issue 4, 2004, Pages 251-267

  Lieberman, Jeffrey A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE PARTIAL AGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PRECLAMOL; PROLACTIN; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; TERGURIDE; UNCLASSIFIED DRUG;

AGITATION; AKATHISIA; ANXIETY DISORDER; BINDING AFFINITY; COGNITIVE DEFECT; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; LIMBIC CORTEX; LONG TERM CARE; NEGATIVE SYNDROME; NIGRONEOSTRIATAL SYSTEM; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RECEPTOR AFFINITY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TUBEROHYPOPHYSEAL TRACT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DOPAMINE; DOPAMINE AGONISTS; HUMANS; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA; SEROTONIN; TREATMENT OUTCOME;

EID: 1642283136     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418040-00005     Document Type: Review

References (81)

1. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizoprenia. Am J Hum Genet 2003; 73 (1): 34-48
2. Coon H, Byerley W, Holik J, et al. Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am J Hum Genet 1993; 52: 327-34
3. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999; 122 (Pt 4): 593-624
4. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and conceptualization. Am J Psychiatry 1991; 148: 1474-86
5. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-4
6. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91: 415-33
7. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990; 4: 2737-44
8. Willner P. The dopamine hypothesis of schizophrenia: current status, future prospects. Int Clin Psychopharmacol 1997; 12: 297-308
9. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9
10. Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Rev 1999; 29: 250-64
11. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358-71
12. Mirnics K, Middleton FA, Marquez A, et al. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28 (1): 53-67
13. Wong DF, Wagner Jr HN, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234 (4783): 1558-63
14. Farde L, Halldin C, Stone-Elander S, et al. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 1987; 92: 278-84
15. 11C]raclopride. Arch Gen Psychiatry 1990; 47: 213-9
16. Laruelle M. Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med 1998; 42: 211-21
17. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385 (6617): 634-6
18. 4 receptors elevated in schizophrenia. Nature 1993; 365: 441-5
19. Lieberman JA, Mailman RB, Duncan G, et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 1998; 44: 1099-117
20. 2 agonists or antagonists? Neuropsychopharmacology 1990; 3: 509-17
21. Krystal JH, Seibel JP, Price LH, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993; 50: 624-35
22. Kahn RS, Siever LJ, Gabriel S, et al. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 1992; 43: 1-12
23. Breier A, Kirkpatrick B, Buchanan RW. Clozapine attenuates metachlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 1993; 34: 492-4
24. Koreen A, Lieberman JA, Alvir J, et al. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychopharmacology 1997; 16 (1): 61-8
25. Nocjar C, Roth BL, Pehek EA. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002; 111 (1): 163-76
26. Martin-Ruiz R, Puig MV, Celada P, et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 2001; 21 (24): 9856-66
27. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77
28. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40 (5): 881-4
29. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999; 4 (5): 418-28
30. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25 (1): 1-27
31. Lewis DA, Pierri JN, Volk DW, et al. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 1999; 46 (5): 616-26
32. Keverne EB. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res Bull 1999; 48: 467-73
33. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
34. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35: S75-86
35. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21 (2 Suppl.): 106S-15S
36. Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia: Amisulpride study group. Psychiatry Res 1999; 88: 107-17
37. Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155: 505-8
38. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73-82
39. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97
40. Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995; 166: 68-72
41. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38
42. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873-83
43. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography (PET) and [11C] raclopride. Neuropsychopharmacology 2002; 27 (2): 248-59
44. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 2000; 295: 853-61
45. Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge, UK: Cambridge University Press, 2000
46. Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol 2001; 86: 376-80
47. Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998; 43: 2-11
48. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109: 411-20
49. Benkert O, Müller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 1995; 5 Suppl.: 43-53
50. 2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997; 321: 105-11
51. Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-{4-[2,3-dichlorophenyl)-1-piperazinyl]-utyoxy}-3,4-dihydro-2 (1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277: 137-43
52. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612-27
53. 2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9
54. 2 receptor antagonist activity. J Pharmacol Exp Ther 1995; 274: 329-36
55. 1A receptor. Eur J Pharamcol 2002; 441: 137-40
56. McQuade RD, Burris KD, Jordan S, et al. Aripiprazole: a dopamine-serotonin system stabilizer [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S176
57. Shapiro DA, Rencock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28 (8): 1400-11
58. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-225
59. Abilify™ (aripiprazole) tablets. Full prescribing information. Tokyo, Japan: Otsuka Pharmaceutical Co Ltd, 2002 Nov
60. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-71
61. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90
62. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 2003; 166: 391-9
63. Daniel DG, Saha AR, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S157
64. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new novel atypical antipsychotic: phase n clinical trial result [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S227
65. Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S186
66. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-56
67. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325-37
68. Comblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S185
69. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003; 61: 123-36
70. Stock E, Marder SR, Saha AR, et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S185
71. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96
72. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001; 62 Suppl. 23: 13-22
73. Casey D, Saha AR, Ali MW, et al. Switching to aripiprazole monotherapy. Int J Neuropsychopharm 2002; 5 Suppl. 1: S187
74. Hesselink MB, van Vliet BJ, Ronken E, et al. DU 127090: a novel partial dopamine agonist with antipsychotic activity. High potency but low efficacy at dopamine D2 receptors. Schizophrenia Research 2003; 60 (1): 108
75. 2 receptors in vitro [abstract]. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: S294
76. Long SK, Feenstra R, Kruse CG, et al. DU 127090: A highly potent, atypical dopamine receptor ligand: partial agonist character in neurochemistry assays in vivo [abstract]. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: S295
77. 1A agonism. Poster presented at the 7th Congress of the European Federation of Neurological Societies; 2003 Aug 30-Sep 2; Helsinki, Finland
78. Van Vliet BJ, Mos J, Van der Heijden JAM, et al. DU 127090: A highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potential [abstract]. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: S293
79. Casey DE, Van Vliet BJ, Kruse CG, et al. DU 127090: A highly potent, atypical dopamine receptor ligand - behavioral effects of DU 127090 in Cebus non-human primates [abtsract]. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: S333
80. 2 agonist series in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated primate model of Parkinson's disease. Poster presented at the 7th Congress of the European Federation of Neurological Societies; 2003 Aug 30-Sep 2; Helsinki, Finland
81. 11C-raclopride by means of positron emission tomography [abstract]. Eur Neuropsychopharmacol 2000; 10 Suppl. 3; S294